Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants
- PMID: 16769711
- PMCID: PMC2675295
- DOI: 10.1136/adc.2006.094474
Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants
Abstract
Objective: To study the association between reduced use of postnatal steroids for bronchopulmonary dysplasia (BPD) in very low birthweight (VLBW) infants and oxygen (O(2))-dependency at 28 days of age and at 36 weeks postmenstrual age.
Design: Large national database study.
Setting: The Israel National VLBW Neonatal Database.
Patients: The sample included infants born between 1997 and 2004, of gestational age 24-32 weeks, who required mechanical ventilation or O(2) therapy. Four time periods were compared: 1997-8 (era 1, peak use), 1999-2000 (era 2, intermediate), 2001-2 (era 3, expected reduction) and 2003-4 (era 4, lowest). The outcome variable "oxygen dependency" was based on clinical criteria. Multivariate regression models were used to account for confounding variables.
Results: Steroid use fell significantly from 23.5% in 1997-8 to 11% in 2003-4 (p<0.005). After adjustment for relevant confounding variables, the odds ratio for O(2) therapy at 28 days in era 4 versus era 1 was 1.75, 95% confidence interval (CI) 1.47 to 2.09 and 1.41, 95% CI 1.15 to 1.73 at 36 weeks postmenstrual age. The mean duration of O(2) therapy increased from 25.3 days (95% CI 23.3 to 26.3) in era 1, to 28.0 days (95% CI 26.6 to 29.4) in era 4. Survival increased from 78.5% in era 1 to 81.6% in era 4 (p<0.005).
Conclusions: The use of steroids has fallen considerably since the awareness of the adverse effects of this treatment. This change has been temporally associated with increased O(2) dependency at 28 days of age and at 36 weeks postmenstrual age. The prolongation of O(2) therapy was modest in degree.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Candidal versus bacterial late-onset sepsis in very low birthweight infants in Israel: a national survey.J Hosp Infect. 2007 Mar;65(3):237-43. doi: 10.1016/j.jhin.2006.12.004. Epub 2007 Feb 2. J Hosp Infect. 2007. PMID: 17275963
-
Hospital variation and risk factors for bronchopulmonary dysplasia in a population-based cohort.JAMA Pediatr. 2015 Feb;169(2):e143676. doi: 10.1001/jamapediatrics.2014.3676. Epub 2015 Feb 2. JAMA Pediatr. 2015. PMID: 25642906
-
Population-based study of bronchopulmonary dysplasia in very low birth weight infants in Switzerland.Eur J Pediatr. 2005 May;164(5):292-7. doi: 10.1007/s00431-005-1623-1. Epub 2005 Feb 15. Eur J Pediatr. 2005. PMID: 15711958
-
Need for supplemental oxygen at discharge in infants with bronchopulmonary dysplasia is not associated with worse neurodevelopmental outcomes at 3 years corrected age.PLoS One. 2014 Mar 19;9(3):e90843. doi: 10.1371/journal.pone.0090843. eCollection 2014. PLoS One. 2014. PMID: 24646665 Free PMC article.
-
Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.Neonatology. 2015;107(4):358-9. doi: 10.1159/000381132. Epub 2015 Jun 5. Neonatology. 2015. PMID: 26044104 Review.
Cited by
-
Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial.BMC Pediatr. 2011 Nov 9;11:102. doi: 10.1186/1471-2431-11-102. BMC Pediatr. 2011. PMID: 22070744 Free PMC article. Clinical Trial.
-
Impact of postnatal corticosteroid use on neurodevelopment at 18 to 22 months' adjusted age: effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants.Pediatrics. 2009 Mar;123(3):e430-7. doi: 10.1542/peds.2008-1928. Epub 2009 Feb 9. Pediatrics. 2009. PMID: 19204058 Free PMC article. Clinical Trial.
-
A comparison of Wisconsin neonatal intensive care units with national data on outcomes and practices.WMJ. 2008 Nov;107(7):320-6. WMJ. 2008. PMID: 19180870 Free PMC article.
-
Targeting inflammation to prevent bronchopulmonary dysplasia: can new insights be translated into therapies?Pediatrics. 2011 Jul;128(1):111-26. doi: 10.1542/peds.2010-3875. Epub 2011 Jun 6. Pediatrics. 2011. PMID: 21646264 Free PMC article. Review.
-
Evidence-Based Neonatal Unit Practices and Determinants of Postnatal Corticosteroid-Use in Preterm Births below 30 Weeks GA in Europe. A Population-Based Cohort Study.PLoS One. 2017 Jan 23;12(1):e0170234. doi: 10.1371/journal.pone.0170234. eCollection 2017. PLoS One. 2017. PMID: 28114369 Free PMC article.
References
-
- Shinwell E S. Current dilemmas in postnatal steroid therapy for chronic lung disease in preterm infants. Biol Neonate 20038423–27. - PubMed
-
- Halliday H L. The effect of postnatal steroids on growth and development. J Perinat Med 200129281–285. - PubMed
-
- Halliday H L, Ehrenkranz R A, Doyle L W. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. In: Cochrane Library. Issue 2. Oxford: Update Software, 2003 - PubMed
-
- Halliday H L, Ehrenkranz R A, Doyle L W. Moderately early postnatal (7–14 days) corticosteroids for preventing chronic lung disease in preterm infants. In: Cochrane Library. Issue 2. Oxford: Update Software, 2003
-
- Halliday H L, Ehrenkranz R A, Doyle L W. Delayed (>3 weeks) corticosteroids for chronic lung disease in preterm infants. In: Cochrane Library Issue 2. Oxford: Update Software, 2003
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources